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Abstract 
 
Introduction 
Because it decreases intubation rate and mortality, NIV has become first-line treatment in 
case of hypercapnic acute respiratory failure (HARF). Whether this approach is equally 
successful for all categories of HARF patients is however debated. We assessed if any clinical 
characteristics of HARF patients were associated with NIV intensity, success, and outcome, in 
order to identify prognostic factors. 
 
Methods 
Retrospective analysis of the clinical database (clinical information system and MDSi) of 
patients consecutively admitted to our medico-surgical ICU, presenting with HARF (defined 
as PaCO2 > 50 mmHg), and receiving NIV between May 2008 and December 2010. 
Demographic data, medical diagnoses (including documented chronic lung disease), reason 
for ICU hospitalization, recent surgical interventions, SAPS II and McCabe scores were 
extracted from the database. Total duration of NIV and the need for tracheal intubation during 
the 5 days following the first hypercapnia documentation, as well as ICU, hospital and one 
year mortality were recorded. Results are reported as median [IQR]. Comparisons were 
carried out with Chi
2
 or Kruskal-Wallis tests, p<0.05 (*). 
 
Results 
Two hundred and twenty patients were included. NIV successful patients received 16 [9-31] 
hours of NIV for up to 5 days. Fifty patients  (22.7%) were intubated 11 [2-34] hours after 
HARF occurence, after having receiving 10 [5-21] hours of NIV. Intubation was correlated 
with increased ICU (18% vs. 6%, p<0.05) and hospital (42% vs. 31%, p>0.05) mortality. 
SAPS II score was related to increasing ICU (51 [29-74] vs. 23 [12-41]%, p<0.05), hospital 
(37% [20-59] vs 20% [12-37], p<0.05) and one year mortality (35% vs 20%, p<0.05). 
Surgical patients were less frequent among hospital fatalities (28.8% vs. 46.3%, p<0.05, RR 
0.8 [0-6-0.9]). Nineteen patients (8.6%) died in the ICU, 73 (33.2%) during their hospital stay 
and 108 (49.1%) were dead one year after HARF. 
 
Conclusion 
The practice to start NIV in all suitable patients suffering from HARF is appropriate. NIV can 
safely and appropriately be used in patients suffering from HARF from an origin different 
from COPD exacerbation. Beside usual predictors of severity such as severity score (SAPS II) 
appear to be associated with increased mortality. Although ICU mortality was low in our 
patients, hospital and one year mortality were substantial. Surgical patients, although 
undergoing a similar ICU course, had a better hospital and one year outcome. 
 
Key-words 
Non-invasive ventilation – Chronic Obstructive Pulmonary Disease –Acute Respiratory 
Failure –Intensive care– Intubation, Intratracheal. 
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Introduction 
 
As the use of non invasive ventilation (NIV) decreases intubation rate, morbidity, duration of 
ICU stay and hospital mortality in case of acute exacerbation of chronic obstructive 
pulmonary disease (COPD) [1], NIV has become the first treatment modality in this situation. 
The interest of using NIV in case of acute respiratory failure in non-COPD patients is much 
more controversial [2]. Even though little information is available regarding the interest of 
using NIV as a first treatment modality in case of hypercapnic acute respiratory failure 
(HARF) of various origins, NIV is widely used in our intensive care unit in this situation 
essentially because NIV is an easy to initiate and non invasive treatment. The main aim of the 
present study was to assess if any clinical characteristics of the patients treated with NIV 
because of hypercapnic acute respiratory failure in our medico-surgical ICU were related to 
NIV success or failure on one hand and to patients’ outcome on the other hand. The second 
aim of the study was to assess whether there was a relationship between these clinical 
characteristics and the intensity of NIV treatment (namely total duration of NIV during the 5 
days following treatment initiation). 
 
The main hypothesis was that, based on our findings, some prognostic factors could be 
identified and provide new information to improve the global management of patients 
suffering from hypercapnic acute respiratory failure of various origins. For instance, such 
information could help the clinician to better define if a specific patient should be intubated 
and when is the most optimal timing to perform the intubation. 
 
Methods 
 
After having obtained the approval of the ethics committee of the Faculty of biology and 
Medicine, we conducted a retrospective study. Patients hospitalized in the Lausanne 
university hospital medico-surgical ICU between May 2008 and December 2010, who 
suffered from hypercapnic acute respiratory failure and received NIV as first treatment 
modality were identified from the ICU clinical information system (Metavision, iMDsoft, 
Needham, MA, USA). Hypercapnic respiratory failure (HARF) was defined as an association 
of clinical characteristics of acute respiratory failure (tachypnoea, respiratory distress, 
hypoxemia, tachycardia) and of documented hypercapnia defined as a PaCO2 value above 50 
mmHg. Hypercapnic episodes obviously due to sedative and/or analgesic administration or 
occurring immediately after extubation were excluded from the analysis.  
 
Patients’ data were collected from the ICU clinical information system and from the medical 
report. Age, past medical history (including documented chronic lung disease and non 
respiratory co-morbidities), reason for ICU admission, the occurrence of a recent surgical 
intervention, SAPS II [3] and MacCabe [4] scores were recorded. Blood gas analyses upon 
ICU admission and during the first diagnosed hypercapnic episode were also recorded from 
the clinical information system. Total duration and number of sessions of NIV during the five 
days following the initial hypercapnic episode were also recorded as well as the need for 
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tracheal intubation and total duration of mechanical ventilation. Additionally, as other 
outcome parameters, ICU mortality and in-hospital mortality were recorded. Finally, one year 
mortality was recorded for most patients, based on the “Registre d’Etat Civil du Canton de 
Vaud”. 
 
Statistical analysis 
 
Statistical analysis was performed using JMP 8 (SAS Institute Inc., Carey, North Carolina). 
For descriptive statistics, categorical variables are reported as percentages and continuous 
values as median (IQR) because of non-normal distribution.  
To explore the relationship between various clinical characteristics and the occurrence of 
different outcomes, we performed Chi2 tests for categorical variables and Kruskal-Wallis 
tests for continuous variables. A p-value of less than 0.05 was considered as statistically 
significant.  
 
4 
 
Results 
 
Patients’ demographic and clinical characteristics are displayed in Table A. Two hundred and 
twenty patients were included in the study. Median age was 70 [59-77] years, mortality 
prediction according to SAPS II score was 25 [13-44] %. Forty-five patients (20.5%) were 
classified as suffering from a rapidly fatal condition according to McCabe’s classification.  
Half of the patients (114) suffered from a previously diagnosed obstructive pulmonary 
disease. Eighty-nine (40.5%) patients underwent a recent surgery before becoming 
hypercapnic after a delay of 19 [12-60] hours.  
 
Blood gas analyses and respiratory outcomes (namely intubation, time to intubation, NIV and 
invasive ventilation (IV) durations are presented in table B. All patients suffered from severe 
respiratory failure attested by the presence of respiratory acidosis in all of them. Among the 
220 patients, 50 (22.7%) were intubated, after a duration of HARF of 11 [2-34] hours. 
Patients requiring intubation received 10 [5-20] hours of NIV beforehand. Patients 
successfully treated with NIV received 16 [9-31] hours of NIV during the 5 days of the study.  
 
Figure A details the evolution of daily respiratory management and outcomes during the first 
5 days following the first documented episode of hypercapnia. The various columns indicate 
the daily cumulative number of events by order of severity. The majority of deaths and 
intubations occurred in the first two days. The number of patients requiring prolonged NIV 
sessions (defined as more than 6 hours per day) decreased over time, ranging from 129 on day 
1 to 19 on day 5. At that time, 7 patients were deceased, 48 were intubated and, as already 
said, 19 required NIV during more than 6 hours per day. The 146 patients remaining were 
either weaned from NIV or already discharged from the ICU on day 5. 
 
Patient’s mortality during the whole ICU stay, during hospital stay and one year after HARF 
episode is presented in Figure B. The information regarding living status was available for all 
patients at hospital discharge and for 197 patients one year after HARF. Among the 220 
patients studied 19 (8.6%) died in the ICU, 73 (33.2%) during their hospital stay and 108 
(49.1%) were dead one year after HARF. Hence, although ICU mortality was relatively 
modest, half of the included patients were dead one year after HARF. 
 
In Tables C and D, various clinical characteristics are compared in relationship to the 
occurrence or non occurrence of the following outcomes, NIV failure (i.e., intubation), ICU 
death (Table C), hospital death and one year mortality (Table D).  
 
NIV duration was shorter in intubated patients. Intubation was correlated with increased 
SAPS II score, while all other variables were not different.  
 
The 19 (8.6%) patients who died during ICU stay had a higher SAPS II predicted mortality 
(51 [29-74] vs. 23 [12-41]%, p<0.05) and a higher intubation rate (47.4% vs 20.4% RR 1.5 
[1.0-2.3], p<0.05). The other clinical variables were not different. 
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The 73 (33.2%) patients who died during hospital stay (including ICU deaths) underwent 
longer mechanical ventilation (31 [12-112] vs. 20 [9-56] hours, p<0.05). They were also older 
than those who survived (75 [67-81] versus 66 [56-76] years old, p<0.05) and were more 
often male patients (69.9% vs. 53.7%, p<0.05, RR 1.5 [1.0-2.3]). Patients deceased in the 
hospital had also a higher SAPSII probability of death (37% [20-59] vs 20% [12-37], p<0.05) 
and higher rapidly fatal McCabe score (31.5% vs 15.0%, p<0.05, RR 1.24 [1.0-1.5]). Of note, 
surgical patients were less frequent among hospital fatalities (28.8% vs. 46.3%, p<0.05, RR 
0.8 [0-6-0.9]). Surgical patients who survived developed HARF more rapidly after their 
procedure (20 [15-50] vs. 43 [19-152] hours, p<0.05). The other clinical variables were not 
different. 
 
Clinical characteristics related to one year mortality were basically comparable to clinical 
characteristics related to hospital mortality: Deceased patients were older (75 [66-80] vs. 64 
[54-73] years old, p<0.05) and more frequently male patients (67.6% vs. 46.3%, p<0.05, RR 
1.7 [1.2-2.3]). They had higher SAPS II probabilities of death (35% vs 20%, p<0.05) and had 
more often rapidly fatal McCabe scores (28.4% vs 12.6%, p<0.05, RR 1.2 [1.1-1.4]). 
Additionally, they underwent less often surgery (28.7% vs. 51.8%, p<0.05) and suffered more 
frequently from chronic pulmonary disease (74.1% vs. 68.8%, p>0.05). Hence, for the 29 
patients who died during the year after their episode of HARF, we found the same clinical 
pattern characteristics than the one associated with hospital mortality. 
 
Considering the whole population, need for intubation was associated with a higher mortality 
during ICU stay (18% vs 5.9%, p<0.05) (Table F). In the population of patients suffering 
from COPD, intubation was more strongly related to an increasing ICU and hospital mortality 
(Table G). 
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Discussion 
In the present study, we assessed both the process of care and various outcomes for ICU 
patients requiring NIV for HARF of different origins in a group of 220 consecutive patients.  
Globally, 50/220 (22.7%) patients had to be intubated. Regarding the timing of intubation, 
most (32) occurred during the first day after the diagnostic of HARF, 10 during the second 
day, and 5 during the third day. Such timing is coherent with Brochard’s seminal study [1]. 
This confirms the general feeling that the first day(s) are critical for the success of NIV in 
case of HARF. Likewise, the number of patients requiring high-intensity NIV decreased 
almost by half every day. Overall, these results suggest that the process of NIV, which 
requires both efficient technology equipments (ventilators, interfaces) and technical skills 
among ICU nurses and respiratory therapists, is efficient in our unit. 
Intubation rate 
In the present study, the intubation rate amounted to 22.7%. This figure is similar to the 
16.4% intubation rate reported in the Cochrane review for patients with COPD exacerbations 
[5]. In a prospective study which included both COPD patients (about 50%) and non COPD 
patients (about 50%) suffering from HARF, intubation rate was 19% for COPD exacerbation 
and 47% for other causes of HARF [6]. We could not confirm this observation as in our study 
intubation rate was correlated neither with COPD nor with surgical admission (Table C). 
Indeed, the only variable significantly correlated with intubation was SAPS score. This latest 
observation is coherent with existing literature, which clearly indicates that intubation is 
correlated with ICU scores of severity [6,7]. Of note, the absence of correlation between 
intubation and factors previously associated with increased intubation rate, such as surgical 
admission [7], presence of COPD [6] or more severe blood gas alterations may appear 
surprising. We have no clear explanation for this finding, and can only speculate that as in our 
study, only patients suffering from severe respiratory acidosis were included, the range of 
arterial gas alteration was too low to show a statistically significant correlation.  
ICU mortality 
ICU mortality remained low, amounting to 8.6%. We could not find published data on ICU 
mortality for comparison. The major reason is that ICU mortality may be markedly influenced 
by ICU discharge policies and specificities of hospital organisation. In most studies, hospital 
mortality is considered as a more robust outcome [3]. In our study, besides SAPS score, the 
only variable correlated with mortality was intubation which is consistent with published data 
[5]. As more severe patients are more likely to be intubated and to die in the ICU or in the 
hospital, it is not possible from our study to determine whether intubation is a causal factor or 
a covariate of mortality. 
Hospital mortality 
To our surprise, hospital mortality amounted to 33.2% in our group of patients, meaning that 
24.6% of our patients died in the hospital after ICU discharge. This result is in sharp contrast 
with the hospitality mortality of the whole population of patients discharged alive from the 
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ICU which amounts to only about 6%. The hospital mortality documented in our patients is 
also much higher than the 10% mortality reported in the Cochrane review for patients 
suffering from acute COPD exacerbation [5], but is rather similar (26%) to the value reported 
in a British audit of 2500 patients [8]. This apparent discrepancy may reflect the difference 
between patients enrolled in a randomised control study and patients included in “real life” 
studies considering all patients.  
Besides disease severity (SAPS II), patients dying in the hospital were older and more 
frequently male patients. They were also more likely classified as suffering from a rapidly 
fatal pre-existing disease (McCabe). Of note, intubation was not correlated with increased 
hospital mortality. All these variables suggest that such patients were likely suffering from 
more advanced chronical diseases. Since resuscitation status was not readily available from 
the patient’s file, it is not possible to know how many patients died while receiving palliative 
care in our study population. However, the limited number of ICU readmission for these 
patients indirectly suggests that there could have been treatment limitations in a large 
proportion of them. 
Another surprising finding was the correlation between surgical admission and reduced 
hospital mortality. Such effect is not directly mediated by a better outcome of NIV for 
surgical patients, since there was no difference for intubation rate (see above). There was even 
a trend toward more surgical patients intubated (50.0% vs. 37.7%, p=0.12). This suggests that 
surgical patients may endure a process leading to a severe acute respiratory failure that might 
be more reversible than medical patients.  
One year mortality 
One year living status was available for 93% of our patients, indicating that at least 29 
supplementary deaths had occurred after hospital discharge. A similar increment of deaths in 
elderly patients discharged alive after successful NIV treatment has recently been described 
by Nava et al [9]. In that study about half of the patients had a do-not-resuscitate–order.  
The same clinical factors correlated with hospital mortality were also found for one year 
mortality. This suggests that such correlations are robust, and that the “protective” effect of 
the surgical admission was long lasting. This reinforces the assumption that surgical patients 
are more likely to recover, once they have overcome acute respiratory failure. 
Study limitations 
We must acknowledge the following study limitations. 
First, our study is a mono-centric study and therefore reports intubation rate, treatment 
modalities and outcomes related to the local treatment practices and beliefs. This means that 
other centres could possibly find different results related to different practices. Second, our 
study is a retrospective one. Although many technical and physiological aspects of patient’s 
condition and management are well documented in the clinical information system, more 
subtle aspects such as treatments limitations may not appear and could have influence some of 
the results, especially hospital mortality. Third, our definition of HARF with a PaCO2 above 
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50 mmHg can be contested as it selected relatively severe patients which could also have 
influenced our results. Finally, the exclusion of hypercapnic episodes obviously due to 
sedative and/or analgesic administration or occurring immediately after extubation could also 
be contested.  
 
Conclusion 
As there were no differences in patient’s respiratory management, especially intubation rate, 
or ICU outcome between patients suffering from COPD or from hypercapnic acute respiratory 
failure of any origin, we can conclude that the practice to start NIV in all suitable patients 
suffering from HARF is appropriate. Hence, NIV can safely and appropriately be used in 
patients suffering from HARF from an origin different from COPD exacerbation. Although 
ICU mortality was low in our patients, hospital and one year mortality were substantial. This 
late mortality appears more related to the irreversibility of underlying chronical disease rather 
that to the treatment modality of acute respiratory failure. Surgical patients, although 
undergoing a similar ICU course, had a better hospital and one year outcome. 
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Table A. Demographic and pulmonary history  
 
N = 220  
Age (y) 70  [59-77] 
Male 130 59.1% 
BMI (kg/m
2
) 24  [23-28] 
BMI less than 18 16 7.3% 
BMI more than 30 42 19.1% 
SAPS II Points 40  [32-49] 
SAPS II Probability (%) 25  [13-44] 
McCabe rapidly fatal 45 20.5% 
Chronical pulmonary disease 157 71.4% 
Obstructive pulmonary 
disease 
114 51.8% 
Restrictive pulmonary 
disease 
18 8.2% 
Mixed obstrucive and 
restrictive  pulmonary disease 
25 11.4% 
No chronical pulmonary 
disease 
18 8.2% 
Tobacco use** 86 39.5% 
NIV or O2 at home 38 17.3% 
Surgical ICU admission 89 40.5% 
Recent surgery to  HARF 
(hours) (n=89) 
21 [16-69] 
* *Current users.   
SAPS = simplified acute physiology score, ICU = Intensive Care Unit, BMI = Body Mass Index, NIV = Non 
Invasive Ventilation 
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Table B. Clinical features and total ventilation for 120 hours 
  
pHa during HARF (n=220) 7.29  [7.24-7.34] 
PaCO2 during HARF (mmHg) (n=220)  62  [54-68] 
PaO2 during HARF (mmHg) (n=220)  79  [69-98] 
PaO2/FiO2 during HARF (n=220) 191.4 [145.9-261.4] 
Hb during HARF (n=220) 116  [101-133] 
Intubated 50  22.7% 
Time to intubation (hours) (n=50) 11 [2-34] 
NIV duration (hours) (n=220) 15  [8-30] 
VI duration (hours) (n=50) 109  [86-118] 
Total V duration (hours) (n=220) 23  [10-70] 
Tracheotomia during ICU stay 13  5.9% 
pHa = Arterial pH, HARF = Hypercapnic Acute Respiratory Failure, Hb = Hemoglobin, NIV = Non-Invasive 
Ventilation, VI = Invasive Ventilation, V = Ventilation, ICU = Intensive Care Unit  
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Figure A. Respiratory management and outcomes during the five days following the 
hypercapnia: The various columns indicate the daily cumulative number of events by order of 
severity (from discharge to death). 
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Figure B: Short- and long-term mortality 
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Table C. Clinical characteristics and short-term outcomes 
Intubated within 120 hours ICU death 
 Yes No p RR Yes No p RR 
Number of patients 50 22.7% 170 77.3%   19 8.6% 201 91.4%   
Age 70 [60-78] 69 [56-96] 0.24  71 [64-75] 70       [59-77] 0.74  
Male 35 70.0% 95 55.9% 0.07  14 73.7% 116 57.7% 0.17  
BMI (kg/m
2
) 24 [22-29] 24 [23-28] 0.80  25 [23-27] 24 [22-29] 1.00  
BMI less than 18 kg/m
2
 4 8.0% 12 7.0% 0.82  0 0% 16 8.0% 0.08  
BMI more than 30 kg/m
2
 11 22.0% 31 18.2% 0.55  3 15.8% 39 19.4% 0.70  
SAPS II points 43.5 [32-60.5] 39 [31-47] ---  52 [42-63] 39 [31-48] ---  
SAPS II (%) 32 [13-69] 23 [12-39] <0.05  51 [29-74]  23 [12-41] <0.05  
McCabe rapidly fatal 13 26.0% 32 18.8% 0.27  12 63.1% 33 16.4% <0.05 2.3 [1.3-4.1] 
Chronic pulmonary disease 33 66.0% 124 72.9% 0.34  11 57.9% 146 72.6% 0.18  
Tabacco use 17 34.0% 69 41.1% 0.60  7 36.8% 79 39.7% 0.81  
NIV/O2 at home 9 18.0% 29 17.1% 0.88  3 15.8% 35 17.4% 0.86  
Surgical ICU admission 25 50.0% 64 37.7% 0.12  4 21.1% 85 42.3% 0.07  
Recent surgery to  HARF (hours) 30  [12-187] 20 [16-64] 0.68  55 [18-143] 20 [16-66] 0.37  
pHa during HARF 7.31 [7.24-7.35] 7.29 [7.24-7.34] 0.34  7.25 [7.18-7.32] 7.29 [7.24-7.34] 0.22  
PaCO2 during HARF 61 [54-66] 62  [54-68] 0.54  61 [56-66] 62 [54-69] 0.71  
PaO2 during HARF 86 [68-108] 77 [69-96] 0.30  76 [73-86] 79 [68-102] 0.47  
PaO2/FiO2 during HARF 184 [148-244] 196 [146-264] 0.45  186 [146-264] 194 [1468-263] 0.84  
Hb during HARF 116 [102-130] 117 [100-133] 0.64  107 [93-125] 117 [102-133] 0.09  
Intubated --- --- --- --- --- --- 9 47.4% 41 20.4% <0.05 1.5 [1.0-2.3] 
Time to intubation (hours) 11 [2-34] --- --- ---  2 [2-28] 11 [2-37] 0.50  
NIV duration (hours) 10  [5-20] 16  [8-31] <0.05  12  [7-18] 16  [8-30] 0.29  
VI duration (hours) 109  [86-118] --- --- ---  118  [92-118] 109 [83-118] 0.50  
Total V duration (hours) 118 [108-121] 16 [8-31] <0.05  97 [13-119] 22 [10-59] <0.05  
SAPS = simplified acute physiology score, ICU = Intensive Care Unit, BMI = Body Mass Index, NIV = Non Invasive Ventilation, pHa = Arterial pH, HARF = Hypercapnic Acute Respiratory 
Failure, Hb = Hemoglobin, NIV = Non-Invasive Ventilation, VI = Invasive Ventilation, V = Ventilation 
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Table D. Clinical characteristics and long-term outcomes 
Hospital death One-year death 
 Yes No p RR Yes No p RR 
Number of patients 73 33.2% 147 66.8%   102 51.8% 95 48.2%   
Age 75 [67-81]  66 [56-76] <0.05  75  [66-81] 66  [58-75] <0.05  
Male 51 69.9% 79 53.7% <0.05 1.5 [1.0-2.3] 69 67.7% 44 46.3% <0.05 1.7 [1.2-2.3] 
BMI (kg/m
2
) 25 [23-28] 24 [22-29] 0.28  24 [23-28] 25 [23-29] 0.48  
BMI less than 18 kg/m
2
 3 4.1% 13 8.8% 0.20  7 6.9% 3 3.2% 0.24  
BMI more than 30 kg/m
2
 16 21.9% 26 17.7% 0.45  18 17.7% 21 22.1% 0.43  
SAPS II points 46 [37-56] 37 [31-46] ---  45 [37-54] 37 [31-43] ---  
SAPS II (%) 37 [20-59] 20 [12-37] <0.05  35  [20-56] 20  [12-31] <0.05  
McCabe rapidly fatal 23 31.5% 22 15.0% <0.05 1.24 [1.0-1.5] 29 28.4% 12 12.6% <0.05 1.2 [1.1-1.4] 
Chronic pulmonary disease 52 71.2% 105 71.4% 0.98  75 73.5% 68 71.6% 0.76  
Tabacco use 23 31.5% 63 43.5% 0.19  34 33.3% 45 47.9% 0.12  
NIV/O2 at home 16 21.9% 22 15.0% 0.20  23 22.6% 15 15.8% 0.23  
Surgical ICU admission 21 28.8% 68 46.3% <0.05 0.8[0.6-0.9] 28 27.5% 45 47.4% <0.05 0.7 [0.6-0.9] 
Recent surgery to HARF (hours) 43  [19-152] 20 [15-50] <0.05  20 [17-116] 23 [15-64] 0.71  
pHa during HARF 7.29  [7.23-7.32] 7.29  [7.24-7.34] 0.33  7.29 [7.24-7.33] 7.27 [7.24-7.33] 0.88  
PaCO2 during HARF 61  [53-67] 61.8 [55-68] 0.47  61 [54-69] 62 [55-68] 0.51  
PaO2 during HARF 75 [70-88] 80 [68-110] 0.07  77 [69-90] 79 [65-99] 0.76  
PaO2/FiO2 during HARF 184 [149-261] 200  [144-266] 0.53  188 [148-261] 185 [142-253] 0.91  
Hb during HARF 113 [99-131] 118 [101-135] 0.28  116 [100-131] 121 [101-140] 0.19  
Intubated 21 28.7% 29 19.7% 0.13  25 24.5% 17 17.9% 0.26  
Time to intubation (hours) 4 [2-26] 18 [3-46] 0.08  7 [2-29] 7 [2-51] 0.36  
NIV duration (hours) 16  [8-32] 15  [8-30] 0.55  16 [9-30] 15 [8-31] 0.68  
VI duration (hours) 116 [94-118] 102 [74-117] 0.08  112  [91-118] 113 [69-118] 0.36  
Total V duration (hours) 31 [12-112] 20 [9-56] <0.05  22 [12-98] 20 [9-50] 0.20  
SAPS = simplified acute physiology score, ICU = Intensive Care Unit, BMI = Body Mass Index, NIV = Non Invasive Ventilation, pHa = Arterial pH, HARF = Hypercapnic Acute Respiratory 
Failure, Hb = Hemoglobin, NIV = Non-Invasive Ventilation, VI = Invasive Ventilation, V = Ventilation 
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Table F. Outcomes related to intubation 
 Intubated Not intubated  
     p RR 
Nombre de patients 50 22.7% 180 77.3%   
ICU death 9 18.0% 10 5.9% <0.05 1.1 [1.0-1.3] 
CHUV death 21 42.0% 52 30.6% 0.13  
One-year death 25 59.5% 77 49.7% 0.26  
NIV = Non-Invasive Ventilation, ICU = Intensive Care Unit 
 
 
 
Table G. Outcomes related to intubation in COPD patients 
 
 COPD with intubation COPD without intubation  
     p RR 
Nombre de patients 27 12.3% 87 39.5%   
ICU death 6 22.2% 3 3.5% <0.05 6.4 [1.7-24.1] 
CHUV death 14 51.9% 26 29.9% <0.05 1.7 [1.1-2.8] 
One-year death 17 68.0% 42 51.2% 0.14  
COPD = Chronic Obstructive Pulmonary DiseaseNIV = Non-Invasive Ventilation, ICU = Intensive Care Unit 
 
 
